Kaydence Pharma – Successful completion of Pre-IND meeting with FDA
Oslo, Norway (15 January 2019) — Kaydence Pharma AS, the development stage pharmaceutical company spun-out of NattoPharma in 2017, reports today that it has successfully completed a pre-IND (Investigational New Drug) meeting with the US Food and Drug Administration (FDA). At the meeting, the FDA addressed questions regarding key components of the planned IND application and the clinical/regulatory pathway for MQ7, Kaydence Pharma’s novel drug candidate for the treatment of arterial stiffness in stable renal transplant recipients with subclinical vitamin K deficiency. “The continued